primary antibodies-benchmark xt ישראל - עברית - Ministry of Health

primary antibodies-benchmark xt

גאמידור דיאגנוסטיקה בע"מ - מומחה - מכשיר וראגנטים לצביעות אימונוהסטוכמיה ואינסיטוהיברידיזציה

סירקדין ישראל - עברית - Ministry of Health

סירקדין

neurim pharmaceuticals limited - melatonin 2 mg - tablets - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

ניאספן 500 מ"ג טבליות מצופות בשחרור ממושך ישראל - עברית - Ministry of Health

ניאספן 500 מ"ג טבליות מצופות בשחרור ממושך

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ניאספן 750 מ"ג טבליות מצופות בשחרור ממושך ישראל - עברית - Ministry of Health

ניאספן 750 מ"ג טבליות מצופות בשחרור ממושך

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ניאספן 1000 מ"ג טבליות מצופות בשחרור ממושך ישראל - עברית - Ministry of Health

ניאספן 1000 מ"ג טבליות מצופות בשחרור ממושך

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

קולירצין ישראל - עברית - Ministry of Health

קולירצין

rafa laboratories ltd - colistimethate sodium - אבקה להכנת תרכיז לאינפוזיה - colistimethate sodium 1000000 u/vial - colistin - colistin - antibiotic for treatment of infections caused by micro-organisms sensitive to colistin.

מסוליד 100 ישראל - עברית - Ministry of Health

מסוליד 100

rafa laboratories ltd - nimesulide - קפליות - nimesulide 100 mg - nimesulide - nimesulide - acute pain.primary dysmenorrhea.

אוקליבה 10 מג ישראל - עברית - Ministry of Health

אוקליבה 10 מג

neopharm ltd, israel - obeticholic acid - טבליות מצופות פילם - obeticholic acid 10 mg - obeticholic acid

אוקליבה 5 מג ישראל - עברית - Ministry of Health

אוקליבה 5 מג

neopharm ltd, israel - obeticholic acid - טבליות מצופות פילם - obeticholic acid 5 mg - obeticholic acid

גמאפלקס ישראל - עברית - Ministry of Health

גמאפלקס

kamada ltd, israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 5 g / 100 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents in:- primary immunodeficiency syndromes with impaired antibody production - hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed- hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation- congenital aids with recurrent bacterial infectionsimmunomodulation in adults, and children and adolescents in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barr? syndrome- kawasaki disease